Overview

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

Status:
Terminated

Trial end date:
2016-09-14

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Riociguat